ArticlePediatric transplantation2026
Hospitalization Costs of Kidney Transplantation Associated With Induction Therapy Among Pediatric Kidney Transplant Recipients: A North American Pediatric Renal Trials and Collaborative Studies and Pediatric Health Information System Collaborative Study.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChoice of induction agent at the time of pediatric kidney transplantation is primarily influenced by recipient characteristics and center practice. The economic implications of this choice have not been reported in a pediatric cohort.
methodsThis is a retrospective study of merged data from North American Pediatric Renal Trials and Collaborative Studies transplant registry with data in the Pediatric Health Information Systems. We estimated costs of the kidney transplant admission analyzed for association with induction agent and clinical factors. Participants were grouped by induction agent: interleukin-2 receptor blocker (IL2RB), anti-thymocyte globulin (ATG), and alemtuzumab. We also estimated inpatient care and other hospital-based services during the first year after transplantation.
resultsA total of 831 children and young adults < 21 years who received a kidney transplant between January 2010 through 2019 were identified. Among these, 50.5% received ATG, 31.3% received IL2RB only, and 18.2% received alemtuzumab. Among clinical characteristics studied, sex and likelihood of pre-emptive transplant were similar among the groups. Though unadjusted index hospitalization costs (IHC) were significantly different among the induction groups, induction choice was not associated with IHC in multivariable analysis. Younger age at the time of transplantation and delayed graft function (DGF) were independently associated with higher IHC. Unadjusted hospital-based costs incurred after discharge from the transplant procedure through the first year after transplantation were similar among induction groups.
conclusionAmong pediatric and young adult kidney transplant recipients, IHC was comparable across induction agents. Younger age at transplantation and DGF were associated with significantly higher IHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.